A Phase 1 Open-Label Study to Assess the Pharmacokinetics of Mirdametinib and Its Metabolite PD-0315209 in Participants With Impaired Hepatic Function and Participants With Normal Hepatic Function
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Mirdametinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors SpringWorks Therapeutics
Most Recent Events
- 04 Jun 2025 New trial record